RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270
by
, , , , ,
Osama A. A. Ahmed
1,2
,
Usama A. Fahmy
1,*,
Shaimaa M. Badr-Eldin
1,3,
Hibah M. Aldawsari
1,
Zuhier A. Awan
4,
Hani Z. Asfour
5,
Ahmed K. Kammoun
6,
Giuseppe Caruso
7
,
Filippo Caraci
7,8,
Anas Alfarsi
1,
Raniyah A. Al-Ghamdi
9,
Rawan A. Al-Ghamdi
10 and
Nabil A. Alhakamy
1,2,11 1
Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
2
Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
3
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
4
Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
5
Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia
6
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
7
Oasi Research Institute-IRCCS, Via Conte Ruggero, 73, 94018 Troina (EN), Italy
8
Department of Drug Sciences, University of Catania, 95125 Catania, Italy
9
Ibn Sina National College for Medical Studies, Clinical Pharmacy Department, Jeddah 22421, Saudi Arabia
10
Ibn Sina National College for Medical Studies, Jeddah 22421, Saudi Arabia
11
Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia
*
Author to whom correspondence should be addressed.
Nanomaterials 2024, 14(2), 174; https://doi.org/10.3390/nano14020174
Submission received: 18 December 2023
/
Accepted: 5 January 2024
/
Published: 12 January 2024
The Journal retracts the article “Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route” [1].
Following the publication, concerns were brought to the attention of the Editorial Office regarding the overlapping figures between publications [1,2], representing different experimental conditions. More specifically, subfigures B and D of Figure 6 in publication [2] are duplicated as subfigures D and C of Figure 6 in publication [1], respectively.
The authors cooperated with the investigation and commented that the mistake occurred while finalizing the figures for both studies, and the wrong image was selected for publication [1]. The authors also provided raw data and other documents related to the histopathological experiments in the reported study. However, the Editorial Board and Editor in Chief determined that the evidence and explanation provided were insufficient to justify the overlap observed, and inconsistencies in the raw data provided meant that serious doubts remained regarding the reliability of the data provided. As a result, the Editorial Board and Editor in Chief were unable to confirm the reliability of the findings and subsequently decided to retract this paper.
This retraction was approved by the Editor in Chief of the journal Nanomaterials.
The authors did not agree to this retraction.
References
- Ahmed, O.A.A.; Fahmy, U.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Awan, Z.A.; Asfour, H.Z.; Kammoun, A.K.; Caruso, G.; Caraci, F.; Alfarsi, A.; et al. RETRACTED: Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270. [Google Scholar] [CrossRef] [PubMed]
- Fahmy, U.A.; Ahmed, O.A.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Okbazghi, S.Z.; Awan, Z.A.; Bakhrebah, M.A.; Alomary, M.N.; Abdulaal, W.H.; Medina, C.; et al. RETRACTED ARTICLE: Optimized Nanostructured Lipid Carriers Integrated into In Situ Nasal Gel for Enhancing Brain Delivery of Flibanserin. Int. J. Nanomed. 2020, 15, 5253–5264. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Ahmed, O.A.A.; Fahmy, U.A.; Badr-Eldin, S.M.; Aldawsari, H.M.; Awan, Z.A.; Asfour, H.Z.; Kammoun, A.K.; Caruso, G.; Caraci, F.; Alfarsi, A.; et al. RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270. Nanomaterials 2024, 14, 174. https://doi.org/10.3390/nano14020174
AMA Style
Ahmed OAA, Fahmy UA, Badr-Eldin SM, Aldawsari HM, Awan ZA, Asfour HZ, Kammoun AK, Caruso G, Caraci F, Alfarsi A, et al. RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270. Nanomaterials. 2024; 14(2):174. https://doi.org/10.3390/nano14020174
Chicago/Turabian StyleAhmed, Osama A. A., Usama A. Fahmy, Shaimaa M. Badr-Eldin, Hibah M. Aldawsari, Zuhier A. Awan, Hani Z. Asfour, Ahmed K. Kammoun, Giuseppe Caruso, Filippo Caraci, Anas Alfarsi, and et al. 2024. "RETRACTED: Ahmed et al. Application of Nanopharmaceutics for Flibanserin Brain Delivery Augmentation Via the Nasal Route. Nanomaterials 2020, 10, 1270" Nanomaterials 14, no. 2: 174. https://doi.org/10.3390/nano14020174
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
